Danielle C. Chinn

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer

Matthew S Lara, William Holland, Danielle C. Chinn et al. · Clinical Lung Cancer · 2016 · 38 citations

Non–small-cell Lung Cancer, Oncology, Met Inhibitor Inc-280 +8

Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies

Danielle C. Chinn, William Holland, Philip C. Mack · Journal of Cancer Research and Clinical Oncology · 2014 · 30 citations

Oncology, Non-small-cell Lung Cancer, Medicine +8

Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines

William Holland, Danielle C. Chinn, Primo N. Lara et al. · Journal of Cancer Research and Clinical Oncology · 2014 · 20 citations · Full text

Hgf-mediated Erlotinib Resistance, Medicine, Pharmacology +8

Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma

Zhijian Duan, Danielle C. Chinn, Mei‐Juan Tu et al. · Translational Oncology · 2019 · 20 citations · Full text

Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy

William Holland, Clifford G. Tepper, Jose E. Pietri et al. · Cancer Chemotherapy and Pharmacology · 2011 · 17 citations

Urology, Genitourinary Cancer, Medicine +6